Facing Alzheimer's Risk Through Genetics

Upon discovering that they have a genetic predisposition to Alzheimer's, three scientists have embarked on a journey to safeguard their cognitive health.

Those who inherit two APOE4 gene variants face a significant probability—60%—of developing Alzheimer's disease by the time they reach 85.

The Genetic Revelation

A small fraction, 2 to 3 percent, of Americans possess this genetic setup and most remain uninformed due to never undergoing genetic screening.

However, three pioneering scientists did opt for testing, discovering that they belong to this high-risk demographic. They are fueled by the goal of protecting their own mental wellbeing as well as aiding others with the APOE4-4 genotype.

June's Story: From Despair to Action

June, who received her unsettling test results from 23andMe in 2023, initially felt like her world was collapsing.

Worried about potential professional and insurance repercussions, June requested anonymity. With her background in biochemistry, she recognized the dire implications immediately.

Facing the prospect of earlier onset than the average population, she was confronted with a grim 7-year timeline.

Her insomnia led her to explore academic literature on Alzheimer's and even to consider extreme measures like physician-assisted end-of-life options to avoid burdening her family.

Eventually, June turned to supportive online communities for people like her.

These networks provided more than just information; they offered genuine connections and solace.

She began implementing lifestyle changes: a Mediterranean diet, regular exercise, and stress management, motivated by the potential for brain health benefits.

June also came across an experimental project at the University of California, San Diego, seeking to determine if rigorous mental and physical exercises could bolster brain health in individuals aged 50 to 85.

By 2024, June was actively participating in virtual reality cycling exercises at UCSD.

These exercises demanded her full cognitive engagement, providing an effective mental workout.

Comprehensive MRI scans and cognitive assessments were integral to this study.

For June, this was transformative, offering insights into effective memory retention strategies.

She is now a vocal advocate for Alzheimer's research, pushing for legislative and regulatory support of potential treatments beneficial to the APOE4-4 group.

David Watson's Pursuit of Solutions

Though physical and mental exercises can potentially postpone Alzheimer's symptoms, David Watson—a neuropsychologist and CEO of the Alzheimer's Research and Treatment Center in Florida—believes this isn’t enough for those with the APOE4 genetic burden.

Carrying the genetic variant suggests a resilience of genetics over lifestyle adjustments alone.

Learning of his genetic risk decades ago, influenced by family experiences, Watson set out to focus his career on discovering pharmaceutical interventions.

His research played a role in bringing new drugs to the market, though personal use was not beneficial for him.

Monoclonal antibody treatments aimed at amyloid plaques in the brain appear unsuitable for Watson and those with similar genetics due to adverse side effects.

A promising drug developed by Alzheon, however, offers hope by preventing plaque formation rather than removal, bypassing such side effects.

Initial results have been encouraging, though not uniformly successful in clinical trials. Watson holds a tempered optimism.

Wendy Nelson's Advocacy

Wendy Nelson, discovering her genetic profile via a 23andMe test, initially felt the urge to keep it under wraps.

Despite understanding the implications due to her scientific expertise, she was unsure of her next steps.

Already leading a healthy, active lifestyle, recognizing her genetic risk in 2022 prompted only a few lifestyle tweaks.

A serendipitous connection led to a public discussion about her condition.

Initially, Nelson felt shielded by the belief that her results would not garner broad attention.

However, as interest grew, she began engaging in various media platforms and advocacy roles, shining light on this genetic issue.

Nelson leverages her visibility to educate and advocate for research, supporting comprehensive governmental and medical inquiry.

Her advocacy also opened doors to dialogues with significant entities like the FDA, aiming to broaden drug approvals that could benefit individuals with her genetic markers.

Nelson believes that collective action within the APOE4-4 community can pave the way for future advancements, echoing the hopes of June and Watson.